期刊
MOLECULAR MEDICINE
卷 26, 期 1, 页码 -出版社
SPRINGER
DOI: 10.1186/s10020-020-00197-9
关键词
Lung adenocarcinoma (LA); Lung adenocarcinoma bone metastasis (LABM); Epithelial growth factor receptor (EGFR); clonal evolution; capture single molecule amplification and resequencing technology (capSMART)
资金
- National Natural Science Foundation of China [81960571, 81560509, 81760566]
- Project of Department of Jiangxi Province Science and Technology Plan [20192ACB70013]
Background Patients newly diagnosed with lung adenocarcinoma with bone metastases (LABM) have poor survival rates after treatment with conventional therapies. To improve outcomes, we retrospectively investigated whether the application of a more comprehensive genetic test of tumor biopsies samples from LABM patients could provide the basis for treatment with more effective tyrosine kinase inhibitors (TKIs) regimens. Methods Fine needle biopsies were taken from the primary tumor (PT) and a secondary bone metastasis (BM) of 17 LABM patients before treatment. Simple genetic profiles for selecting therapies were initially obtained using an ARMS-PCR test forEGFRandALKfusion mutations. More detailed genetic profiles of somatic exon SNVs and CNVs in 457 cancer-related genes were retrospectively derived using capture single molecule amplification and resequencing technology (capSMART). Results ARMS-PCR identified 14EGFRpositive, 3EGFRnegative and 1ALKfusion positive patient. A therapy regimen incorporating TKIs Gefitinib and Crizotinib was offered to theEGFRandALKfusion positive patients, respectively. With the exception of two patients, molecular profiling of matching PT and BM biopsies identified a highly shared somatic variant fingerprint, although the BMs exhibited additional genomic instability. In six of 13EGFRpositive patients and in all threeEGFRnegative patients, examination of the genetic profiles identified additional clinically significant mutations that are known or experimental drug targets for treatment of lung cancer. Conclusion Our findings firstly suggest that treatment regimens based on comprehensive genetic assessment of newly diagnosed LABM patients should target both the PT and secondary BMs, including rogue clones with potential to form new BMs. Second, the additional information gained should allow clinicians to design and implement more personalized treatment regimens and potentially improve outcomes for LABM patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据